Advertisement
Screener

Opus Genetics, Inc. (IRD) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

Opus Genetics, Inc. Operating Cash Flow

Opus Genetics, Inc. (IRD) reported Operating Cash Flow of -$24.68 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06

  • Opus Genetics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$11.95M.
  • Opus Genetics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$12.73M.
  • Opus Genetics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$9.83M.
  • Opus Genetics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$6.16M.
  • Opus Genetics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$35.25M.
  • Opus Genetics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$25.58M.
  • Opus Genetics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$1.11M, a 107.77% decline from fiscal 2022.
  • Opus Genetics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was $14.31M.
Period endNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 3 month as first filedNet Cash Provided by (Used in) Operating Activities 6 monthNet Cash Provided by (Used in) Operating Activities 6 month as first filedNet Cash Provided by (Used in) Operating Activities 9 monthNet Cash Provided by (Used in) Operating Activities 9 month as first filedNet Cash Provided by (Used in) Operating Activities 12 monthNet Cash Provided by (Used in) Operating Activities 12 month as first filed
2026-06-30-$11.95M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$24.68M
10-Q · filed 2026-08-06
-$34.51M
derived: sum of 3 quarters · filed 2026-08-06
-$40.67M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31-$12.73M
10-Q · filed 2026-05-12
-$22.56M
derived: sum of 2 quarters · filed 2026-05-12
-$28.72M
derived: sum of 3 quarters · filed 2026-05-12
-$38.99M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31-$9.83M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
-$15.99M
derived: sum of 2 quarters · filed 2026-03-12
-$26.26M
derived: sum of 3 quarters · filed 2026-08-06
-$35.25M
10-K · filed 2026-03-12
2025-09-30-$6.16M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
-$16.43M
derived: sum of 2 quarters · filed 2026-08-06
-$25.42M
10-Q · filed 2025-11-12
-$32.86M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30-$10.27M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$19.26M
10-Q · filed 2026-08-06
-$26.70M
derived: sum of 3 quarters · filed 2026-08-06
-$31.83M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31-$8.99M
10-Q · filed 2026-05-12
-$16.43M
derived: sum of 2 quarters · filed 2026-05-12
-$21.56M
derived: sum of 3 quarters · filed 2026-05-12
-$28.85M
derived: sum of 4 quarters · filed 2026-05-12
2024-12-31-$7.44M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
-$12.57M
derived: sum of 2 quarters · filed 2026-03-12
-$19.86M
derived: sum of 3 quarters · filed 2026-03-12
-$25.58M
10-K · filed 2026-03-12
2024-09-30-$5.13M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
-$12.42M
derived: sum of 2 quarters · filed 2025-11-12
-$18.14M
10-Q · filed 2025-11-12
-$13.59M
derived: sum of 4 quarters · filed 2025-11-12
2024-06-30-$7.29M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13
-$13.01M
10-Q · filed 2025-08-13
-$8.46M
derived: sum of 3 quarters · filed 2025-08-13
-$11.46M
derived: sum of 4 quarters · filed 2025-08-13
2024-03-31-$5.72M
10-Q · filed 2025-05-15
-$1.17M
derived: sum of 2 quarters · filed 2025-05-15
-$4.17M
derived: sum of 3 quarters · filed 2025-05-15
-$3.18M
derived: sum of 4 quarters · filed 2025-05-15
2023-12-31$4.55M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31
$1.54M
derived: sum of 2 quarters · filed 2025-03-31
$2.53M
derived: sum of 3 quarters · filed 2025-03-31
-$1.11M
10-K · filed 2025-03-31
2023-09-30-$3.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
-$2.01M
derived: sum of 2 quarters · filed 2024-11-12
-$5.66M
10-Q · filed 2024-11-12
$23.13M
derived: sum of 4 quarters · filed 2024-11-12
2023-06-30$989.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13
-$2.66M
10-Q · filed 2024-08-13
$26.13M
derived: sum of 3 quarters · filed 2024-08-13
$21.64M
derived: sum of 4 quarters · filed 2024-08-13
2023-03-31-$3.65M
10-Q · filed 2024-05-10
$25.14M
derived: sum of 2 quarters · filed 2024-05-10
$20.65M
derived: sum of 3 quarters · filed 2024-05-10
$16.84M
derived: sum of 4 quarters · filed 2024-05-10
2022-12-31$28.79M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08
$24.29M
derived: sum of 2 quarters · filed 2024-03-08
$20.48M
derived: sum of 3 quarters · filed 2024-03-08
$14.31M
10-K · filed 2024-03-08
2022-09-30-$4.50M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13
-$8.31M
derived: sum of 2 quarters · filed 2023-11-13
-$14.48M
10-Q · filed 2023-11-13
-$20.12M
derived: sum of 4 quarters · filed 2023-11-13
2022-06-30-$3.81M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11
-$9.98M
10-Q · filed 2023-08-11
-$15.63M
derived: sum of 3 quarters · filed 2023-08-11
-$19.21M
derived: sum of 4 quarters · filed 2023-08-11
2022-03-31-$6.17M
10-Q · filed 2023-05-15
-$11.82M
derived: sum of 2 quarters · filed 2023-05-15
-$15.40M
derived: sum of 3 quarters · filed 2023-05-15
-$19.73M
derived: sum of 4 quarters · filed 2023-05-15
2021-12-31-$5.65M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30
-$9.23M
derived: sum of 2 quarters · filed 2023-03-30
-$13.56M
derived: sum of 3 quarters · filed 2023-03-30
-$19.37M
10-K · filed 2023-03-30
2021-09-30-$3.58M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04
-$7.91M
derived: sum of 2 quarters · filed 2022-11-04
-$13.72M
10-Q · filed 2022-11-04
-$18.08M
derived: sum of 4 quarters · filed 2022-11-04
2021-06-30-$4.33M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12
-$10.14M
10-Q · filed 2022-08-12
-$14.50M
derived: sum of 3 quarters · filed 2022-08-12
-$15.55M
derived: sum of 4 quarters · filed 2022-08-12
2021-03-31-$5.81M
10-Q · filed 2022-05-13
-$10.17M
derived: sum of 2 quarters · filed 2022-05-13
-$11.23M
derived: sum of 3 quarters · filed 2022-05-13
-$11.88M
derived: sum of 4 quarters · filed 2022-05-13
2020-12-31-$4.36M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24
-$5.41M
derived: sum of 2 quarters · filed 2022-03-24
-$6.07M
derived: sum of 3 quarters · filed 2022-03-24
-$6.80M
10-K · filed 2022-03-24
2020-09-30-$1.06M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12
-$1.71M
derived: sum of 2 quarters · filed 2021-11-12
-$2.44M
10-Q · filed 2021-11-12
-$4.14M
10-Q · filed 2020-10-29
$2.53M
derived: sum of 4 quarters · filed 2021-11-12
2020-06-30-$651.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12
-$1.38M
10-Q · filed 2021-08-12
-$3.01M
10-Q · filed 2020-08-14
$3.59M
derived: sum of 3 quarters · filed 2021-08-12
$1.21M
derived: sum of 4 quarters · filed 2021-08-12
2020-03-31-$732.00K
10-Q · filed 2021-05-07
-$1.22M
10-Q · filed 2020-05-07
$4.24M
derived: sum of 2 quarters · filed 2021-05-07
$1.86M
derived: sum of 3 quarters · filed 2021-05-07
$55.09K
derived: sum of 4 quarters · filed 2021-05-07
2019-12-31$4.97M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11
$2.59M
derived: sum of 2 quarters · filed 2021-03-11
$787.10K
derived: sum of 3 quarters · filed 2021-03-11
-$3.59M
10-K · filed 2021-03-11
-$10.28M
10-K · filed 2020-02-21
2019-09-30-$2.38M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29
-$4.18M
derived: sum of 2 quarters · filed 2020-10-29
-$8.56M
10-Q · filed 2020-10-29
-$13.18M
derived: sum of 4 quarters · filed 2020-10-29
2019-06-30-$1.81M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14
-$6.19M
10-Q · filed 2020-08-14
-$10.81M
derived: sum of 3 quarters · filed 2020-08-14
-$14.97M
derived: sum of 4 quarters · filed 2020-08-14
2019-03-31-$4.38M
10-Q · filed 2020-05-07
-$9.00M
derived: sum of 2 quarters · filed 2020-05-07
-$13.17M
derived: sum of 3 quarters · filed 2020-05-07
-$17.62M
derived: sum of 4 quarters · filed 2020-05-07
2018-12-31-$4.62M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21
-$8.79M
derived: sum of 2 quarters · filed 2020-02-21
-$13.24M
derived: sum of 3 quarters · filed 2020-02-21
-$18.84M
10-K · filed 2020-02-21
2018-09-30-$4.17M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06
-$8.62M
derived: sum of 2 quarters · filed 2019-11-06
-$14.22M
10-Q · filed 2019-11-06
-$17.92M
derived: sum of 4 quarters · filed 2019-11-06
2018-06-30-$4.45M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07
-$10.05M
10-Q · filed 2019-08-07
-$13.76M
derived: sum of 3 quarters · filed 2019-08-07
-$17.20M
derived: sum of 4 quarters · filed 2019-08-07
2018-03-31-$5.60M
10-Q · filed 2019-05-10
-$9.30M
derived: sum of 2 quarters · filed 2019-05-10
-$12.75M
derived: sum of 3 quarters · filed 2019-05-10
-$16.85M
derived: sum of 4 quarters · filed 2019-05-10
2017-12-31-$3.70M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07
-$7.15M
derived: sum of 2 quarters · filed 2019-03-07
-$11.25M
derived: sum of 3 quarters · filed 2019-03-07
-$15.42M
10-K · filed 2019-03-07
2017-09-30-$3.45M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-02
-$7.55M
derived: sum of 2 quarters · filed 2018-11-02
-$11.72M
10-Q · filed 2018-11-02
2017-06-30-$4.10M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03
-$8.27M
10-Q · filed 2018-08-03
2017-03-31-$4.17M
10-Q · filed 2018-05-04

Similar stocks

Stock NameCountryMarket CapPE Ratio
RELMADA THERAPEUTICS, INC. (RLMD)United States$0.406B-11.92
Arcturus Therapeutics Holdings Inc. (ARCT)$0.402B-2.05
GALECTIN THERAPEUTICS INC (GALT)United States$0.399B-11.06
ARS Pharmaceuticals, Inc. (SPRY)United States$0.414B-3.70
Atea Pharmaceuticals, Inc. (AVIR)United States$0.414B-2.26
Turn Therapeutics Inc. (TTRX)United States$0.397B-25.68
DiaMedica Therapeutics Inc. (DMAC)United States$0.423B-10.11
PROTHENA CORP PUBLIC LTD CO (PRTA)Ireland$0.428B-11.53
Rezolute, Inc. (RZLT)United States$0.382B-6.45
CYPHERPUNK TECHNOLOGIES INC. (CYPH)United States$0.438B-75.63